New Content  edit
Get The App!

Loading the player...
Novel Therapeutics for Thrombosis and Hemostasis
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Dr. Jeffrey Weitz of McMaster University discusses the utility, efficacy of novel oral anticoagulants (NOACs) in reducing risk for VTE and preventing stroke in AF patients.The relative efficacy and safety of the NOACs in reducing intracranial hemorrhage compared to warfarin is considered. He then discusses new clinical trials with these agents designed around morbidity and mortality endpoints that are expected to lead to new indications for the NOACs. Finally, Dr. Weitz considers new,emerging targets in the coagulation cascade, such as F11 and F12, that are upstream of FXa and are viable targets for development of novel anticoagulants.